The NHS will recieve a cash increase of £33.9 billion a year by 2023-24 compared to 2018-19 budgets.
News
AstraZeneca, Theragnostics sign PARPi development agreement
The licensing agreement enables the company’s “freedom to operate globally in the diagnostic field of certain selected radionuclide-labelled PARPi”.
Snack tax could be ‘more effective’ than sugary drink tax
The news comes after Cancer Research UK found that obesity causes more cases of certain cancers than smoking.
Breakthrough status for Janssen’s RSV vaccine
RSV is a highly prevalent, very contagious respiratory infection and a leading cause of bronchitis and pneumonia.
J&J launches ‘Make Blood Cancer Visible’ campaign
The company has released a short documentary and five mini-films, outlining the symptoms that led patients to their diagnosis.
Just over 1 week left to enter into the 2019 Marketer of the Year competition!
Entry for the 2019 PharmaTimes Marketer of the Year competition will be closing for entry on the 16th September.
Cidara, Mundipharma team up to commercialise Rezafungin
The total transaction value could exceed $568 million.
Teva undergoes rebranding
The “refreshed visual identity” includes a new digital platform entitled ‘Life Effects’.
Women ‘risking’ lives, not doing bowel screening tests
While 81% of women take part in cervical cancer screening and 73% in breast cancer screening, only 60% of women take part in bowel screening.
UK in ‘desperate’ need of thousands more GPs
The number of fully qualified, full-time equivalent GPs fell by 576 in the year from June 2018 to June 2019.
ABPI launches NHS, industry partnership guideline
Joint projects include identification of undiagnosed patients, improving patient adherence to medicines and contributions to nurse services.
NICE nod for Novartis’ Luxturna
The treatment has been approved for RPE65-mediated inherited retinal dystrophies.
Greater Manchester NHS declares climate emergency
Organisations are already making progress in reducing carbon emissions and tackling environment degradation.
Gyroscope Theraputics secures £50.4m Series B financing
Syncona and Cambridge Innovation Capital will contribute £48 million and £2.4 million, respectively.
NHS warns parents as ‘asthma season’ hits
At this time of year cases can more than double.
